Stockreport

Why Johnson & Johnson Is Eyeing Protagonist Therapeutics: The Rationale [Seeking Alpha]

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF PTGX's lead assets, Icotrokinra and Rusfertide, offer significant potential, with peak combined sales estimated at $7 billion, appealing to JNJ's immunology strategy. [Read more]